Related Experiment Video

Updated: Aug 26, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes

R Schmidt1, F Baumann, H Knüpfer

  • 1Institute of Clinical Pharmacology, University of Leipzig, Härtelstr. 16-18, D-04107 Leipzig, Germany. schmidtr@medizin.uni-leipzig.de

British Journal of Cancer
|February 19, 2004
PubMed

Insights

This study found that breast tumors express CYP3A4 and CYP2C9 enzymes, enabling intratumoral metabolism of ifosfamide. This discovery suggests potential for modulating ifosfamide

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Ifosfamide is a prodrug requiring cytochrome P450 bioactivation for its anti-tumor effects.
  • Intratumoral metabolism of ifosfamide, beyond hepatic pathways, remains largely uncharacterized.

Purpose of the Study:

  • To investigate the expression of key cytochrome P450 enzymes (CYP3A4, CYP2C9, CYP2B6) in breast cancer tissue.
  • To determine the capacity for ifosfamide metabolism within tumor microsomes.

Main Methods:

  • Western blotting was used to detect CYP3A4, CYP2C9, and CYP2B6 protein expression in breast cancer tissues.
  • High-performance liquid chromatography (HPLC/UV) and liquid chromatography-mass spectrometry (LC/MS) were employed to quantify ifosfamide metabolites.

Main Results:

  • CYP3A4 was detected in all 11 tested breast tumors, with varying expression levels.
  • CYP2C9 was present in 9 out of 9 tested breast tumors.
  • CYP2B6 protein was not detected in 10 tested samples.
  • Breast cancer microsomes exhibited ifosfamide N-dechloroethylation capacity, but 4-hydroxylation metabolites were undetectable.

Conclusions:

  • The presence of CYP3A4 and CYP2C9 in breast tumors indicates a potential for intratumoral ifosfamide biotransformation.
  • This study provides the first evidence of ifosfamide turnover in human breast cancer microsomal preparations.
  • Modulating intratumoral ifosfamide metabolism could significantly impact its therapeutic efficacy.

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...